Suthesh Sivapalaratnam, Steve Austin, Ulrike Lorch, Thomas York, Andrew Want, Ashley Gosnell, Prafull S. Gandhi, Henrik Østergaard, Erik Bjornson, Tara O'Meara, Benny Sorensen, Roger E.G. Schutgens, Catherine Rea

Exciting findings from a Phase 1/2 first-in-human study on HMB-001 for Glanzmann thrombasthenia have been published in Blood (2023).

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event